基于中医阴阳学说探讨胆汁酸/短链脂肪酸代谢紊乱与肝性脑病的关系

颜璐怡; 陈玮钰; 王涵; 冯雯倩; 杜洋; 田雪如; 洪杨; 毛德文; 付蕾; 姚春

doi:10.12449/JCH250733

基于中医阴阳学说探讨胆汁酸/短链脂肪酸代谢紊乱与肝性脑病的关系

DOI: 10.12449/JCH250733

颜璐怡¹,
陈玮钰¹,
王涵³,
冯雯倩¹,
杜洋¹,
田雪如¹,
洪杨¹,
毛德文⁴,
付蕾²,
姚春^2, , ,

1.
广西中医药大学研究生院，南宁 530200
2.
广西中医药大学教学实验实训中心，南宁 530200
3.
广西中医药大学第一附属医院中内教研室，南宁 530023
4.
广西中医药大学第一附属医院肝病科，南宁 530023

基金项目:

国家自然科学基金 (82260899);

广西中药壮瑶药多学科交叉创新团队 (GZKJ2301);

广西重点研发计划 (Guike AB22035076);

广西疑难重症中医诊疗研究团队 (2022A001);

广西研究生教育创新计划 (YCBZ2024149);

广西研究生教育创新计划 (YCSY2025051);

广西研究生教育创新计划 (YCSY2025050);

广西研究生教育创新计划 (YCSY2025056)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：姚春、毛德文负责研究选题并拟定写作思路；冯雯倩、杜洋负责设计论文框架；田雪如、洪杨负责收集、整理文献材料；颜璐怡、陈玮钰负责文章撰写；付蕾、王涵负责修改论文；姚春负责指导论文及定稿。

详细信息

通信作者:
姚春， yaoc@gxtcmu.edu.cn （ORCID： 0000-0003-2903-8814）

计量
- 文章访问数: 411
- HTML全文浏览量: 189
- PDF下载量: 20
- 被引次数: 0
出版历程
- 收稿日期: 2025-04-10
- 录用日期: 2025-05-19
- 出版日期: 2025-07-25

Association between bile acid/short-chain fatty acid metabolic disorders and hepatic encephalopathy based on the traditional Chinese medicine theory of Yin and Yang

1.
Graduate School，Guangxi University of Chinese Medicine，Nanning 530200，China
2.
Teaching Experiment and Training Center，Guangxi University of Chinese Medicine，Nanning 530200，China
3.
Department of Internal Medicine of Traditional Chines Medicine
4.
Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

National Natural Science Foundation of China (82260899);

Guangxi Traditional Chinese Medicine and Zhuang Yao Medicine Interdisciplinary Innovation Team (GZKJ2301);

Guangxi Key Research and Development Plan Project (Guike AB22035076);

Guangxi Research Team of TCM Diagnosis and Treatment of Difficult and Critical Diseases (2022A001);

Guangxi Graduate Education Innovation Program Project (YCBZ2024149);

Guangxi Graduate Education Innovation Program Project (YCSY2025051);

Guangxi Graduate Education Innovation Program Project (YCSY2025050);

Guangxi Graduate Education Innovation Program Project (YCSY2025056)

More Information

Corresponding author: YAO Chun， yaoc@gxtcmu.edu.cn （ORCID： 0000-0003-2903-8814）

摘要

摘要: 肝性脑病是继发于严重肝脏疾病的神经精神综合征。近年研究表明，肝性脑病的发生与胆汁酸/短链脂肪酸代谢紊乱密切相关。阴阳学说作为中医学理论的核心，为阐释胆汁酸-短链脂肪酸与肝性脑病的关系提供了独特视角。胆汁酸功能类阳，主疏泄、助代谢；短链脂肪酸属阴，安内守藏，维系肠系屏障、抗御炎毒。二者在生理状态下相互制约、互根互用，共同调控“肠-肝-脑轴”动态平衡。基于此，通过调节胆汁酸与短链脂肪酸的代谢失衡，有望从中西医协同角度恢复肝性脑病患者的阴阳动态平衡。
- 肝性脑病 /
- 阴阳学说 /
- 胆汁酸类 /
- 脂肪酸类
Abstract: Hepatic encephalopathy is a neuropsychiatric syndrome secondary to severe liver disease. Recent studies have shown that the development of hepatic encephalopathy is closely associated with bile acid/short-chain fatty acid metabolic disorder. As the core theory of traditional Chinese medicine， the theory of Yin and Yang provides a unique perspective for analyzing the association between bile acids/short-chain fatty acids and hepatic encephalopathy. Bile acids function like Yang， governing the free flow of Qi and assisting in metabolic processes， while short-chain fatty acids belong to Yin， maintaining internal stability and conservation， preserving the intestinal barrier， and combating inflammation and toxins. Bile acids and short-chain fatty acids constrain each other and are interdependent to regulate the dynamic equilibrium of the gut-liver-brain axis. On this basis， by regulating the metabolic imbalance of bile acids and short-chain fatty acids， it is expected to restore the dynamic balance of Yin and Yang in patients with hepatic encephalopathy under the synergistic intervention of traditional Chinese medicine and Western medicine.
- Hepatic Encephalopathy /
- Yin Yang Theory /
- Bile Acid /
- Fatty Acids

HTML全文

图 1 中医阴阳失衡视域下BA/SCFA代谢紊乱与肝性脑病的关系

Figure 1. The relationship between BA/SCFA metabolism disorder and hepatic encephalopathy from the perspective of yin-yang imbalance in traditional Chinese medicine

下载: 全尺寸图片幻灯片

参考文献(50)

[1]	Chinese Society of Hepatology of Chinese Medical Association. Chinese guidelines on the management of hepatic encephalopathy in cirrhosis(2024)[J]. Chin J Hepatol, 2024, 32( 9): 799- 812. DOI: 10.3760/cma.j.cn501113-20240630-00309. 中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32( 9): 799- 812. DOI: 10.3760/cma.j.cn501113-20240630-00309.
[2]	ELSAID MI, RUSTGI VK. Epidemiology of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24( 2): 157- 174. DOI: 10.1016/j.cld.2020.01.001.
[3]	LIU RP, KANG JD, SARTOR RB, et al. Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant[J]. Hepatology, 2020, 71( 2): 611- 626. DOI: 10.1002/hep.30827.
[4]	USAMI M, MIYOSHI M, YAMASHITA H. Gut microbiota and host metabolism in liver cirrhosis[J]. World J Gastroenterol, 2015, 21( 41): 11597- 11608. DOI: 10.3748/wjg.v21.i41.11597.
[5]	JIANG HN, MAO DW, YE QL, et al. Research progress on TCM syndrome differentiation and treatment of hepatic encephalopathy[J]. Shaanxi J Tradit Chin Med, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042. 蒋海南, 毛德文, 叶倩伶, 等. 中医辨证论治肝性脑病研究进展[J]. 陕西中医, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042.
[6]	LI JY, XIN XY, YANG HS. Experience of QIAN Ying in treating minimal hepatic encephalopathy[J]. China J Tradit Chin Med Pharm, 2021, 36( 7): 4022- 4024. 李晶滢, 辛喜艳, 杨华升. 钱英辨治轻微型肝性脑病经验[J]. 中华中医药杂志, 2021, 36( 7): 4022- 4024.
[7]	WANG MG, WANG N, MAO DW, et al. Analysis on TCM etiology and pathogenesis of mild hepatic encephalopathy[J]. Mod Tradit Chin Med, 2017, 37( 2): 55- 57. DOI: 10.13424/j.cnki.mtcm.2017.02.022. 王明刚, 王娜, 毛德文, 等. 轻微型肝性脑病中医病因病机探析[J]. 现代中医药, 2017, 37( 2): 55- 57. DOI: 10.13424/j.cnki.mtcm.2017.02.022.
[8]	BAI WJ, PAN PP, SHI QL, et al. Discussion on the pathogenic theory of“turbidity-toxin” in hepatic encephalopathy[J]. J Basic Chin Med, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005. 柏文婕, 潘佩佩, 石清兰, 等. 基于“浊毒致病” 学说探讨肝性脑病病因病机[J]. 中国中医基础医学杂志, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005.
[9]	WU ZP, ZHANG YQ, YAO C, et al. Construction and practice of the theory of“turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine[J]. J Clin Hepatol, 2025, 41( 2): 370- 374. DOI: 10.12449/JCH250226. 吴智鹏, 张钰琴, 姚春, 等. 肝性脑病中医/壮医“浊毒致病” 理论及防治策略的构建与实践[J]. 临床肝胆病杂志, 2025, 41( 2): 370- 374. DOI: 10.12449/JCH250226.
[10]	XIE XX, DU LN, GUO ZY, et al. Role of apical sodium-dependent bile acid transporter in hepatobiliary diseases[J]. J Clin Hepatol, 2024, 40( 1): 199- 203. DOI: 10.12449/JCH240133. 谢晓暄, 杜丽娜, 郭紫云, 等. 顶端钠依赖性胆汁酸转运蛋白(ASBT)在肝胆疾病中的作用[J]. 临床肝胆病杂志, 2024, 40( 1): 199- 203. DOI: 10.12449/JCH240133.
[11]	LARABI AB, MASSON HLP, BÄUMLER AJ. Bile acids as modulators of gut microbiota composition and function[J]. Gut Microbes, 2023, 15( 1): 2172671. DOI: 10.1080/19490976.2023.2172671.
[12]	XIE XM, ZHANG BY, FENG S, et al. Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice[J]. Microbiol Spectr, 2025, 13( 4): e0315024. DOI: 10.1128/spectrum.03150-24.
[13]	WANG XN, XIE GX, ZHAO AH, et al. Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis[J]. J Proteome Res, 2016, 15( 4): 1126- 1134. DOI: 10.1021/acs.jproteome.5b00217.
[14]	ZHU F, ZHENG SD, ZHAO M, et al. The regulatory role of bile acid microbiota in the progression of liver cirrhosis[J]. Front Pharmacol, 2023, 14: 1214685. DOI: 10.3389/fphar.2023.1214685.
[15]	WEN JB, ZHU FQ, CHEN WG, et al. Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl₄-induced cirrhotic rats[J]. PLoS One, 2014, 9( 8): e106082. DOI: 10.1371/journal.pone.0106082.
[16]	WANG Y, YU YB, LI LX, et al. Bile acid-dependent transcription factors and chromatin accessibility determine regional heterogeneity of intestinal antimicrobial peptides[J]. Nat Commun, 2023, 14( 1): 5093. DOI: 10.1038/s41467-023-40565-7.
[17]	XIE GX, WANG XN, JIANG RQ, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure[J]. EBioMedicine, 2018, 37: 294- 306. DOI: 10.1016/j.ebiom.2018.10.030.
[18]	XUE R, SU LY, LAI SY, et al. Bile acid receptors and the gut-liver axis in nonalcoholic fatty liver disease[J]. Cells, 2021, 10( 11): 2806. DOI: 10.3390/cells10112806.
[19]	ZENG L, HUANG JX, WANG Y, et al. Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters[J]. J Appl Toxicol, 2024, 44( 11): 1725- 1741. DOI: 10.1002/jat.4667.
[20]	LU JL, GAO YT, GONG Y, et al. Lycium barbarum L. Balanced intestinal flora with YAP1/FXR activation in drug-induced liver injury[J]. Int Immunopharmacol, 2024, 130: 111762. DOI: 10.1016/j.intimp.2024.111762.
[21]	XIAO YT, WANG WP, PENG SC, et al. Farnesoid X receptor agonist tropifexor detoxifies ammonia by regulating the glutamine metabolism and urea cycles in cholestatic livers[J]. Eur J Pharmacol, 2024, 966: 176334. DOI: 10.1016/j.ejphar.2024.176334.
[22]	XING C, HUANG X, WANG DX, et al. Roles of bile acids signaling in neuromodulation under physiological and pathological conditions[J]. Cell Biosci, 2023, 13( 1): 106. DOI: 10.1186/s13578-023-01053-z.
[23]	DEMORROW S. Bile acids in hepatic encephalopathy[J]. J Clin Exp Hepatol, 2019, 9( 1): 117- 124. DOI: 10.1016/j.jceh.2018.04.011.
[24]	QUINN M, MCMILLIN M, GALINDO C, et al. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms[J]. Dig Liver Dis, 2014, 46( 6): 527- 534. DOI: 10.1016/j.dld.2014.01.159.
[25]	MCMILLIN M, FRAMPTON G, GRANT S, et al. Bile acid-mediated sphingosine-1-phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice[J]. Front Cell Neurosci, 2017, 11: 191. DOI: 10.3389/fncel.2017.00191.
[26]	NORENBERG MD, RAMA RAO KV, JAYAKUMAR AR. Mechanisms of ammonia-induced astrocyte swelling[J]. Metab Brain Dis, 2005, 20( 4): 303- 318. DOI: 10.1007/s11011-005-7911-7.
[27]	CHEON SY, KIM MY, KIM J, et al. Hyperammonemia induces microglial NLRP3 inflammasome activation via mitochondrial oxidative stress in hepatic encephalopathy[J]. Biomed J, 2023, 46( 5): 100593. DOI: 10.1016/j.bj.2023.04.001.
[28]	LIU PY, WANG YB, YANG G, et al. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis[J]. Pharmacol Res, 2021, 165: 105420. DOI: 10.1016/j.phrs.2021.105420.
[29]	LI GF, LIN J, ZHANG C, et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease[J]. Gut Microbes, 2021, 13( 1): 1968257. DOI: 10.1080/19490976.2021.1968257.
[30]	ZHU RR, LIU LW, ZHANG GZ, et al. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis[J]. Biosci Rep, 2023, 43( 6): BSR20222524. DOI: 10.1042/BSR20222524.
[31]	WANG Q, CHEN CX, ZUO S, et al. Integrative analysis of the gut microbiota and faecal and serum short-chain fatty acids and tryptophan metabolites in patients with cirrhosis and hepatic encephalopathy[J]. J Transl Med, 2023, 21( 1): 395. DOI: 10.1186/s12967-023-04262-9.
[32]	ZHANG SM, ZHAO JW, XIE F, et al. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease[J]. Obes Rev, 2021, 22( 11): e13316. DOI: 10.1111/obr.13316.
[33]	BASHIARDES S, SHAPIRO H, ROZIN S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5( 9): 782- 794. DOI: 10.1016/j.molmet.2016.06.003.
[34]	FOCK E, PARNOVA R. Mechanisms of blood-brain barrier protection by microbiota-derived short-chain fatty acids[J]. Cells, 2023, 12( 4): 657. DOI: 10.3390/cells12040657.
[35]	BLOOM PP, LUÉVANO JM Jr, MILLER KJ, et al. Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy[J]. Ann Hepatol, 2021, 25: 100333. DOI: 10.1016/j.aohep.2021.100333.
[36]	LIU JM, JIN YJ, YE YL, et al. The neuroprotective effect of short chain fatty acids against sepsis-associated encephalopathy in mice[J]. Front Immunol, 2021, 12: 626894. DOI: 10.3389/fimmu.2021.626894.
[37]	HARRISON IF, DEXTER DT. Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson’s disease?[J]. Pharmacol Ther, 2013, 140( 1): 34- 52. DOI: 10.1016/j.pharmthera.2013.05.010.
[38]	RIZZOLO D, KONG B, TAYLOR RE, et al. Bile acid homeostasis in female mice deficient in Cyp7a1 and Cyp27a1[J]. Acta Pharm Sin B, 2021, 11( 12): 3847- 3856. DOI: 10.1016/j.apsb.2021.05.023.
[39]	DUCASTEL S, TOUCHE V, TRABELSI MS, et al. The nuclear receptor FXR inhibits Glucagon-Like Peptide-1 secretion in response to microbiota-derived Short-Chain Fatty Acids[J]. Sci Rep, 2020, 10( 1): 174. DOI: 10.1038/s41598-019-56743-x.
[40]	PAN LY, YU Z, LIANG XL, et al. Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling[J]. Hepatol Commun, 2023, 7( 2): e0039. DOI: 10.1097/HC9.0000000000000039.
[41]	ZAUFEL A, van de WIEL SMW, YIN L, et al. Secondary(Iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions[J]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867( 8): 166153. DOI: 10.1016/j.bbadis.2021.166153.
[42]	WANG ZY, QIANG X, PENG YJ, et al. Design and synthesis of bile acid derivatives and their activity against colon cancer[J]. RSC Med Chem, 2022, 13( 11): 1391- 1409. DOI: 10.1039/d2md00220e.
[43]	GU M, ZHAO P, ZHANG SY, et al. Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice[J]. Br J Pharmacol, 2019, 176( 7): 847- 863. DOI: 10.1111/bph.14570.
[44]	KAEWARSAR E, CHAIYASUT C, LAILERD N, et al. Optimization of mixed inulin, fructooligosaccharides, and galactooligosaccharides as prebiotics for stimulation of probiotics growth and function[J]. Foods, 2023, 12( 8): 1591. DOI: 10.3390/foods12081591.
[45]	WANG N, WANG MG, MAO DW, et al. Clinical observation of rhubarb decoction in the treatment of type A hepatic encephalopathy[J]. Lishizhen Med Mater Med Res, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053. 王娜, 王明刚, 毛德文, 等. 大黄煎剂治疗A型肝性脑病的临床疗效观察[J]. 时珍国医国药, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053.
[46]	HU Z, CHENG XH, CAI J, et al. Emodin alleviates cholestatic liver injury by modulating Sirt1/Fxr signaling pathways[J]. Sci Rep, 2024, 14( 1): 16756. DOI: 10.1038/s41598-024-67882-1.
[47]	HAN SQ, HA W, SHI YP. Research progress on anti-inflammatory effect of Rhei Radix et Rhizoma and its active components[J]. Chin Tradit Herb Drugs, 2023, 54( 1): 303- 316. DOI: 10.7501/ j.issn.0253-2670.2023.01.032. 韩思琪, 哈伟, 师彦平. 大黄及其有效成分抗炎作用的研究进展[J]. 中草药, 2023, 54( 1): 303- 316. DOI: 10.7501/ j.issn.0253-2670.2023.01.032.
[48]	LIU ZH, PENG Y, SUN CZ, et al. Evaluation of therapeutic effects of Mume Fructus powder and water decoction on Crohn’s rats based on in vitro human gastrointestinal metabolism[J]. Chin Tradit Herb Drugs, 2022, 53( 19): 6054- 6067. DOI: 10.7501/j.issn.0253- 2670.2022.19.012. 刘治华, 彭颖, 孙崇智, 等. 基于体外人源胃肠道代谢评价乌梅粉和水煎剂对克罗恩大鼠的治疗作用[J]. 中草药, 2022, 53( 19): 6054- 6067. DOI: 10.7501/j.issn.0253- 2670.2022.19.012.
[49]	WEN XD, WANG CL, XING SM, et al. Current advances in understanding neuroprotective effect of Wumei(mume fructus) in neurodegenerative diseases[J]. Chin Arch Tradit Chin Med, 2024, 42( 1): 41- 45. DOI: 10.13193/j.issn.1673-7717.2024.01.008. 文晓东, 王春玲, 邢诗曼, 等. 乌梅对神经退行性疾病的保护作用研究进展[J]. 中华中医药学刊, 2024, 42( 1): 41- 45. DOI: 10.13193/j.issn.1673-7717.2024.01.008.
[50]	DU YQ, WANG M, XU J, et al. Investigation of therapeutic effects of rhubarb decoction retention Enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics[J]. J Pharm Biomed Anal, 2023, 230: 115392. DOI: 10.1016/j.jpba.2023.115392.